Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma Europe has acquired the license for commercialization of the treatment for advanced prostate cancer Eligard from TOLMAR, a northern Colorado based pharma R&D, manufacturing and commercial operations company with specific focus in therapeutic areas of dental, dermatology, and oncology.
Subscribe to our email newsletter
Astellas Pharma Europe registered and launched luteinizing hormone-releasing hormone (LHRH) agonist Eligard in majority of European countries.
Under the terms of the new agreement, the commercialization of Eligard will be expanded to the Middle East, North Africa, CIS, Central Asia and Asian markets such as China, Taiwan, Thailand, Hong Kong, the Philippines and Indonesia.
The new agreement could strengthen the presence of the therapeutic area, as well as a bridgehead for the entry into the therapeutic area of oncology, Astellas’ third prioritized area alongside urology and transplant in emerging markets including Asia.